Bayer and Onyx have ongoing clinical trials for individuals with kidney cancer. For a more comprehensive list of Nexavar® (sorafenib) clinical trials in a variety of tumor types, please visit clinicaltrials.gov or call 866-639-2827.
Phase 3 Study of Nexavar Versus Sunitinib in Adjuvant Setting - ASSURE *
Study Design: Randomized, placebo-controlled study
Patients: Patients with advanced RCC that has been removed by surgery
Purpose: To compare the efficacy of Nexavar versus sunitinib versus placebo by assessing the differences in disease progression and overall survival
Location: Various sites in the United States and Canada
Phase 3 Study of Nexavar for 3 years vs. 1 year in Adjuvant Setting - SORCE *
Study Design: Randomized, placebo-controlled study
Patients: Patients with advanced RCC that has been removed by surgery
Purpose: To compare the efficacy of Nexavar treatment for 3 years vs. Nexavar treatment for 1 year vs. placebo by assessing differences in disease-free survival, as well as evaluate other measures of efficacy and safety
Location: United Kingdom
* Not a company-sponsored trial
Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011
- SymbolONXX
- Last43.71 +0.22
- Open43.46
- High43.81
- Low42.49
- Volume1139204
Latest News
-
05/19/2011
-
05/18/2011
-
05/18/2011
-
05/18/2011
-
05/19/2011
-
05/18/2011
-
05/18/2011
-
05/18/2011
-
05/6/2021
-
05/4/2021
-
04/28/2011
-
04/21/2011
-
03/28/2011
-
03/11/2021
-
03/2/2022
-
02/24/2011
-
02/23/2011
-
02/15/2011
-
02/3/2021
-
01/31/2011
-
01/4/2021
-
12/7/2021
-
12/6/2021
-
11/18/2010
-
11/10/2021
-
11/9/2021
-
11/4/2021
-
11/3/2021
-
10/26/2010
-
10/7/2021
-
10/7/2021
-
10/7/2021
-
09/16/2010
-
09/8/2021
-
09/7/2021
-
08/4/2021
-
08/3/2021
-
07/28/2010
-
07/26/2010
-
07/23/2010
-
07/21/2010
-
06/14/2010
-
06/14/2010
-
06/8/2021
-
06/8/2021
-
06/5/2021
-
06/4/2021
-
06/1/2022
-
05/21/2010
-
05/20/2010
-
05/11/2021
-
05/5/2021
-
05/4/2021
-
05/4/2021
-
04/27/2010
-
03/16/2010
-
03/1/2022
-
02/23/2010
-
02/16/2010
-
02/2/2022
-
02/2/2022
-
02/1/2022
-
01/5/2021
-
12/11/2021
-
12/10/2021
-
12/7/2021
-
12/7/2021
-
12/6/2021
-
12/4/2021
-
11/25/2009
-
11/16/2009
-
11/11/2021
-
11/10/2021
-
11/4/2021
-
11/3/2021
-
10/29/2009
-
10/27/2009
-
10/23/2009
-
10/12/2021
-
10/12/2021
-
10/11/2021
-
09/30/2009
-
09/28/2009
-
09/24/2009
-
09/23/2009
-
09/15/2009
-
09/4/2021
-
09/2/2022
-
08/6/2021
-
08/6/2021
-
08/4/2021
-
08/4/2021
-
07/29/2009
-
07/22/2009
-
06/2/2022
-
06/1/2022
-
05/28/2009
-
05/20/2009
-
05/17/2009
-
05/14/2009
-
05/12/2021
-
05/6/2021
-
05/5/2021
-
04/28/2009
-
04/26/2009
-
04/26/2009
-
03/10/2021
-
03/3/2021
-
02/23/2009
-
02/12/2021
-
01/6/2021
-
01/5/2021
-
12/23/2008
-
11/6/2021
-
11/6/2021
-
11/5/2021
-
10/31/2008
-
10/29/2008
-
09/18/2008
-
08/21/2008
-
08/15/2008
-
08/5/2021
-
07/31/2008
-
07/30/2008
-
07/28/2008
-
07/23/2008
-
06/19/2008
-
06/4/2021
-
06/2/2022
-
05/16/2008
-
05/16/2008
-
05/8/2021
-
05/6/2021
-
05/5/2021
-
04/29/2008
-
04/24/2008
-
03/11/2021
-
03/11/2021
-
02/26/2008
-
02/19/2008
-
02/19/2008
-
02/18/2008
-
02/18/2008
-
02/6/2021
-
01/25/2008
-
01/2/2022
-
11/19/2007
-
11/6/2021
-
10/30/2007
-
10/25/2007
-
10/4/2021
-
10/3/2021
-
09/21/2007
-
09/18/2007
-
08/27/2007
-
08/20/2007
-
08/7/2021
-
07/31/2007
-
06/27/2007
-
06/21/2007
-
06/19/2007
-
06/18/2007
-
06/4/2021
-
05/25/2007
-
05/23/2007
-
05/9/2021
-
05/2/2022
-
04/27/2007
-
03/15/2007
-
03/8/2021
-
02/15/2007
-
02/12/2021
-
02/12/2021
-
02/9/2021
-
02/8/2021
-
02/1/2022
-
01/24/2007
-
01/10/2021
-
01/2/2022
-
12/4/2021
-
12/4/2021
-
11/7/2021
-
11/1/2022
-
10/12/2021
-
09/29/2006
-
08/8/2021
-
08/1/2022
-
07/24/2006
-
07/20/2006
-
06/13/2006
-
06/12/2021
-
06/6/2021
-
06/5/2021
-
06/1/2022
-
05/25/2006
-
05/10/2021
-
05/4/2021
-
05/3/2021
-
04/28/2006
-
04/27/2006
-
04/27/2006
-
04/26/2006
-
04/18/2006
-
03/30/2006
-
03/24/2006
-
03/2/2022
-
02/16/2006
-
02/16/2006
-
02/9/2021
-
02/8/2021
-
01/31/2006
-
01/5/2021